Stakeholders Must ‘Fully Engage’ If WHO’s Medicines Access Platform Is To Succeed
Executive Summary
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”
You may also be interested in...
WHO Medicines Access Platform ‘Compromised’ By Industry Involvement
A new World Health Organization platform for discussing access to medicines could be too heavily influenced by the pharmaceutical industry, says the NGO Health Action International. The European industry federation EFPIA disagrees.
New WHO Access Platform Could Mean Tiered Pricing In Europe
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.